GlaxoSmithKline

GlaxoSmithKline is a global healthcare company based in the United Kingdom, dedicated to improving health outcomes by providing innovative and high-quality healthcare products. The company operates through three main divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Its Pharmaceuticals unit features a diverse range of innovative and established medicines, with a strong focus on respiratory diseases and HIV. The research and development efforts emphasize immunology, genetics, and advanced technologies. GSK's Vaccines division is notable for its extensive portfolio and innovative pipeline, delivering over two million vaccine doses daily to populations in over 160 countries. The Consumer Healthcare segment focuses on developing and marketing a variety of well-regarded brands in categories such as pain relief, respiratory health, oral health, digestive health, nutrition, and skin health. Through its commitment to scientific advancement and public health, GlaxoSmithKline seeks to enable people to lead healthier lives.

Roger Connor

President, Global Vaccines

Mike Elmore

SVP and Chief Information Security Officer

Moncef Slaoui

Chairman of Vaccines

Nick Tate

VP Digital Innovation

54 past transactions

IDRx

Acquisition in 2025
IDRx is a clinical-stage biopharmaceutical company focused on developing precision therapies for oncology, specifically targeting gastrointestinal stromal tumors. The company specializes in designing combination therapies that utilize engineered drug combinations to address key tumor escape mechanisms, aiming to enhance treatment efficacy and prolong patient responses. By creating these targeted therapies, IDRx seeks to revolutionize cancer treatment and support healthcare professionals in delivering more effective medicines to patients.

Asceneuron

Series C in 2024
Asceneuron SA is a biotechnology company based in Lausanne, Switzerland, founded in 2012, that focuses on discovering and developing therapeutics for neurodegenerative disorders with significant unmet medical needs. The company targets conditions such as progressive supranuclear palsy, orphan tauopathies, Alzheimer’s disease, and Parkinson’s disease. Asceneuron aims to develop orally bioavailable small molecule drugs that address both symptomatic relief and disease progression for these debilitating conditions. Tauopathies, characterized by the accumulation of tau protein deposits in the brain, are a key area of focus, as they currently lack effective treatments. With the increasing prevalence of Alzheimer's disease posing a major healthcare challenge, Asceneuron aspires to become a leading entity in the biotech sector by providing innovative and more effective therapeutic options for patients suffering from neurodegenerative diseases. The company operates as a subsidiary of Merck KGaA.

Aiolos Bio

Acquisition in 2024
Long Description: Aiolos Bio is a biotech company focused on developing therapies for respiratory diseases like asthma as well as other immune conditions. The company is initially focused on advancing AIO-001, a monoclonal antibody therapy for moderate-to-severe asthma that only requires dosing every 6 months. Aiolos Bio was founded by an accomplished team with decades of drug development experience and leadership in the biotech industry.

Canadian Centre for Vaccinology

Grant in 2023
Canadian Centre for Vaccinology is an integrated collaborative interdisciplinary vaccine research team committed to excellent research.

Bellus Health

Acquisition in 2023
Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

WaVe Life Sciences

Post in 2022
Wave Life Sciences Ltd. is a clinical-stage genetic medicine company focused on developing innovative RNA-based therapies. Utilizing its proprietary PRISM platform, the company designs, optimizes, and produces stereopure oligonucleotides aimed at addressing genetic defects. By targeting ribonucleic acid (RNA), Wave aims to either diminish the production of harmful proteins or convert dysfunctional proteins into functional ones. The company's primary focus is on neurology, particularly disorders affecting the central and neuromuscular systems. Wave Life Sciences has established research and collaboration agreements with major pharmaceutical companies, including Pfizer and Takeda, to further advance its therapeutic programs. Founded in 2012 and headquartered in Singapore, Wave Life Sciences is dedicated to delivering transformative treatments for patients with genetically defined diseases.

Spero Therapeutics

Post in 2022
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Affinivax

Acquisition in 2022
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, focused on developing innovative vaccines using its proprietary Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins into a single vaccine, thereby enhancing immune responses against a variety of infectious diseases affecting both children and adults. Affinivax targets several significant pathogens, including Streptococcus pneumoniae, bacterial nosocomial infections, Salmonella typhi, and Staphylococcus aureus. The company aims to create vaccines that not only provide broader disease coverage compared to existing options but also address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from the expertise of leading professionals in infectious diseases and vaccines, and it has received backing from the Bill & Melinda Gates Foundation, along with an exclusive license from Boston Children’s Hospital for its MAPS technology.

Sierra Oncology

Acquisition in 2022
Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for patients with hematology and oncology needs. The company's lead drug candidate, momelotinib, is an orally bioavailable inhibitor targeting JAK1, JAK2, and ACVR1, which has undergone two completed Phase 3 trials for myelofibrosis treatment. Additionally, Sierra Oncology is advancing SRA737, a small molecule inhibitor of Checkpoint kinase 1 currently in Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase, which is in preclinical development. Founded in 2003 and headquartered in Vancouver, Canada, Sierra Oncology aims to provide targeted therapies for rare forms of cancer, leveraging scientific expertise to address limitations in existing treatments and improve patient outcomes. The company was previously known as ProNAi Therapeutics, Inc. before its name change in January 2017.

LifeMine Therapeutics

Series C in 2022
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated platform that combines genomics, artificial intelligence, and synthetic biology. This innovative Avatar-Rx platform utilizes high-throughput microbiology, data science, machine learning, genome engineering, and automation to explore the fungal biosphere for novel genetically encoded molecules with specific biological functions. By integrating chemoinformatic-assisted drug optimization and advanced chemical synthesis with biotransformation, LifeMine Therapeutics aims to advance a pipeline of new medicines into development.

Adrestia Therapeutics

Series A in 2020
Adrestia Therapeutics Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing therapeutics aimed at restoring biological balance in damaged, diseased, and dying cells. Founded in 2017, the company specializes in synthetic rescue, a method that decodes the complexity of genetic networks to identify innovative treatment approaches for various diseases. Adrestia Therapeutics provides basic research, applied research, and experimental development services to advance its mission in the biotechnology industry.

CureVac

Corporate Round in 2020
CureVac is a clinical-stage biopharmaceutical company based in Germany, established in 2000, that specializes in developing vaccines and therapies utilizing messenger ribonucleic acid (mRNA). The company focuses on both prophylactic and therapeutic applications of mRNA, enabling the human body to produce proteins that combat various diseases. CureVac's innovative pipeline includes mRNA-based cancer immunotherapies, such as CV9104, which is in Phase IIb development for prostate cancer, as well as RNActive vaccines against infectious diseases and RNArt molecular therapies designed to stimulate the production of therapeutic proteins. Additionally, the company has collaborated with GSK to advance second-generation vaccines for seasonal influenza and COVID-19, alongside an avian influenza vaccine, while also exploring mRNA therapies for oncology and other conditions affecting the liver and eyes.

Vir Biotechnology

Post in 2020
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

SetPoint Medical

Venture Round in 2019
SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Sitari Pharmaceuticals

Acquisition in 2019
Sitari Pharmaceuticals is a operator of a biotechnology company intended to develop treatments for multiple disease indications with an initial focus in celiac disease.

SpringWorks Therapeutics

Series B in 2019
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

TESARO

Acquisition in 2018
Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

23andMe

Corporate Round in 2018
23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Spero Therapeutics

Series B in 2016
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

Atreca

Series A in 2015
Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, characterized by a novel mechanism of action. ATRC-101 has demonstrated reactivity in vitro with a significant majority of human cancer samples, including ovarian, non-small cell lung, colorectal, and breast cancers. Atreca employs a unique technology to identify antibodies produced during immune responses without prior knowledge of antigens. The company collaborates strategically with Merck Sharp & Dohme Corp. to pinpoint antigenic targets of selected antibodies that may have applications in oncology. Founded in 2010, Atreca is dedicated to advancing innovative treatments for cancer.

Gladius Pharmaceuticals

Series A in 2015
Gladius Pharmaceuticals Inc. is a biotechnology company based in Montréal that focuses on developing innovative antibiotics to combat life-threatening, multi-drug-resistant bacterial infections. The firm is dedicated to creating novel drug candidates that offer broad-spectrum efficacy against gram-negative pathogens. Its antibiotics are designed to assist in the empiric treatment of these infections and have the potential to replace older generation cephalosporins, thereby enabling healthcare providers to treat bacterial infections more effectively.

Spero Therapeutics

Series A in 2015
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. Founded in 2013, the company is advancing several product candidates, including tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic aimed at treating MDR gram-negative infections in adults. Additionally, Spero is developing SPR206, an intravenous agent for MDR gram-negative infections in hospital settings, and SPR720, an oral antibiotic targeting pulmonary non-tuberculous mycobacterial disease. The company collaborates with various partners, including Meiji Seika Pharma to support tebipenem HBr's development and the Bill & Melinda Gates Medical Research Institute for SPR720. Spero Therapeutics employs a focused approach to drug development, emphasizing novel mechanisms to address the urgent need for effective therapeutics against serious bacterial infections.

GlycoVaxyn

Acquisition in 2015
GlycoVaxyn AG is a biopharmaceutical company based in Schlieren, Switzerland, specializing in the development and manufacture of biological conjugation vaccines aimed at preventing bacterial infections. Established in 2004, the company utilizes recombinant DNA technology to create immunogenic glycoprotein conjugate vaccines for various bacterial diseases, including pneumococcal and nosocomial infections. GlycoVaxyn's innovative approach allows for the conjugation of carbohydrates to proteins, resulting in well-characterized molecules with high consistency and reproducibility across batches. This technology supports the development of new prophylactic and therapeutic vaccines, contributing to advancements in the treatment and prevention of bacterial infections. As of early 2015, GlycoVaxyn operates as a subsidiary of GlaxoSmithKline plc.

Silarus Therapeutics

Series A in 2014
Silarus Therapeutics is developing therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. Erythroferrone is a recently-discovered hormone that regulates the iron supply for red blood cell production. Iron deficiency, also known as anemia, is a condition in which blood does not contain the normal amount of red blood cells or lacks the proper amount of hemoglobin. This, in turn, lowers the amount of oxygen-rich blood in circulation, causing shortness of breath, dizziness or headaches.

Thyritope Biosciences

Series A in 2014
Thyritope Biosciences is developing therapeutics that target thyroid stimulating auto-antibodies, which are the causative drivers of Graves' hyperthyroidism and Graves' orbitopathy. Graves' disease is an autoimmune disorder caused by antibodies that over-stimulate the thyroid, causing excessive thyroid hormone production. The same antibodies stimulate the tissue around the eyes, resulting in an increase of orbital fat and extra-ocular muscle volume which causes the bulging of the eyes characteristic of Graves' orbitopathy.

Sitari Pharmaceuticals

Series A in 2013
Sitari Pharmaceuticals is a operator of a biotechnology company intended to develop treatments for multiple disease indications with an initial focus in celiac disease.

SetPoint Medical

Series C in 2013
SetPoint Medical is a clinical-stage bioelectronic medicine company based in Valencia, California, focused on developing implantable neuromodulation devices aimed at treating chronic autoimmune diseases. The company is creating a platform that stimulates the vagus nerve to activate the body's natural inflammatory reflex, leading to a systemic immune-restorative effect. This innovative approach offers an alternative treatment option for conditions such as rheumatoid arthritis and inflammatory bowel disease, with the potential for reduced risks and costs compared to traditional drug therapies. SetPoint Medical, originally known as Innovative Metabolics Inc. until its name change in 2008, aims to provide patients and healthcare providers with effective solutions for managing debilitating inflammatory diseases.

Okairos

Acquisition in 2013
Okairos AG is a biopharmaceutical company that specializes in the discovery and development of genetic T-cell vaccines, with a significant focus on combating the hepatitis C virus. The company is also involved in providing health and allied services. Headquartered in Basel, Switzerland, Okairos operates in Rome and Naples, Italy. It has expertise in gene delivery technologies and scalable viral-vector manufacturing processes, which facilitate the advancement of vaccines and advanced therapies. By utilizing state-of-the-art GMP facilities, Okairos supports biotech companies in transitioning their genetic vaccines and medicinal products from preclinical stages to commercial readiness.

NeRRe Therapeutics

Series A in 2012
NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, specializing in the development of neurokinin (NK) receptor antagonists for clinical and preclinical use. Founded in 2012, the company focuses on creating innovative therapies to address conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at treating intense pruritus caused by targeted anti-cancer therapies. In addition to orvepitant, NeRRe's portfolio includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, a Phase I-ready NK-1 antagonist, and NT-432, a clinical candidate. The company's work targets common and chronic conditions, offering new treatment options for patients suffering from refractory or unexplained cough and other debilitating symptoms.

Human Genome Sciences

Acquisition in 2012
Human Genome Sciences is a biopharmaceutical company that specializes in the development of innovative pharmaceutical products through genomic research. The company is focused on advancing its pipeline of therapies, with three products currently in late-stage clinical development. By leveraging genomic insights, Human Genome Sciences aims to address unmet medical needs and improve patient outcomes in various therapeutic areas.

Amicus Therapeutics

Post in 2012
Amicus Therapeutics, Inc. is a biotechnology company dedicated to the discovery, development, and commercialization of therapies for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company focuses on developing innovative treatments, including Galafold, an orally administered pharmacological chaperone for Fabry disease. Amicus is also advancing its pipeline with a Phase 3 clinical study of AT-GAA for Pompe disease. The company's research includes a range of first-in-class small molecules designed to treat lysosomal storage diseases by stabilizing misfolded enzymes in patients. This therapeutic approach potentially enhances the effectiveness of enzyme replacement therapies. Amicus Therapeutics has established collaborations with institutions such as Nationwide Children's Hospital and the University of Pennsylvania to further its research and development efforts.

Cellzome

Acquisition in 2012
CellZome is a pharmaceutical company based in Heidelberg, Baden-Württemberg, that specializes in the discovery, development, and commercialization of kinase-targeted drugs aimed at treating inflammatory diseases. Founded in 2000, the company focuses on creating a pipeline of kinase inhibitors that act on inflammatory mediators, offering oral therapeutic options for conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis, and asthma.

Epizyme

Venture Round in 2011
Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of novel epigenetic medicines for cancer and other serious diseases. The company has developed Tazemetostat, an EZH2 inhibitor approved for the treatment of metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed follicular lymphoma and high-risk diffuse large B-cell lymphoma, as well as in patients with platinum-resistant solid tumors and castration-resistant prostate cancer. Epizyme also works on other product candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, along with inhibitors targeting PRMT5 and PRMT1 for different types of cancers. Established in 2007, Epizyme collaborates with several prominent organizations to advance its research and development efforts.

Concert Pharmaceuticals

Venture Round in 2011
Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drugs for autoimmune and central nervous system disorders. The company employs an innovative precision deuterium chemistry platform to enhance the properties of established drug molecules, which enables the creation of new chemical entities with potential efficacy and safety advantages. Notable product candidates include CTP-543, currently in Phase III trials for alopecia areata, CTP-692 for schizophrenia in Phase II trials, and AVP-786, which targets neurological and psychiatric disorders in Phase III trials. Concert Pharmaceuticals also engages in strategic collaborations with various pharmaceutical companies to support its development efforts. Founded in 2006 and based in Lexington, Massachusetts, the company aims to streamline research and development processes, reducing associated risks and costs while advancing its therapeutic pipeline.

Maxinutrition Group

Acquisition in 2010
MaxiNutrition is a prominent manufacturer of protein-enhanced functional nutrition products based in the United Kingdom. As a leading player in the European sports nutrition market, MaxiNutrition operates under several brands, including Maximuscle, Maxifuel, and Maxitone. Maximuscle caters to individuals focused on muscle gain, strength, and power, while Maxifuel offers products specifically designed for endurance athletes seeking optimal performance. Additionally, Maxitone targets health-conscious women aiming for toning and weight management. The company provides a diverse range of sports supplements, including protein products, energy and recovery aids, and various training accessories, ensuring customers have access to a comprehensive selection of recreational goods.

Semprus BioSciences

Series B in 2010
Semprus BioSciences is a biomedical company based in Cambridge, Massachusetts, focused on advancing medical device technology. The company has developed an innovative antimicrobial coating technology designed for vascular access catheters, which aims to reduce both microbial adherence and thrombus accumulation throughout the device's lifecycle. This breakthrough in surface modification represents a significant advancement in the medical device market, allowing for the coating of devices of various sizes, shapes, and materials. Semprus has successfully raised a total of $28.5 million in equity financing, with notable investments from firms such as SR One and Foundation Medical Partners.

Nanjing MeiRui Pharma Co.

Acquisition in 2010
Nanjing MeiRui Pharma Co., Ltd. operates as a pharmaceutical business with a strong portfolio of urology and allergy products, including Prostat for benign prostatic hyperplasia and Sheniting for overactive bladder syndrome.

Laboratorios Phoenix

Acquisition in 2010
Laboratorios Phoenix is a global pharmaceutical company headquartered in Argentina. It specializes in the manufacture and distribution of a wide range of pharmaceutical products, including branded generic medications. The company's offerings encompass various therapeutic areas, such as cardiovascular health, gastroenterology, metabolic disorders, and urology. Additionally, Laboratorios Phoenix produces antiseptics, over-the-counter medications, dietary and nutritional supplements, as well as vitamin and mineral complexes. Through its diverse product pipeline, the company aims to meet the healthcare needs of patients both locally and internationally.

NovaMin Technology

Acquisition in 2010
NovaMin Technology provides a range of oral hygiene solutions. The company was founded by Randy Scott in 2004 and is based in Alachua, Florida.

NeuroTherapeutics Pharma

Series B in 2010
NeuroTherapeutics Pharma, Inc., a biopharmaceutical company, develops therapeutics for patients suffering from central nervous system disorders. It focuses on epilepsy, neuropathic, and acute pain disorders of the nervous system. The company was incorporated in 2006 and is based in Chicago, Illinois.

Genmab

Post in 2009
Genmab is a biotechnology company based in Copenhagen that specializes in the development of fully human antibody therapeutics aimed at treating cancer and other serious diseases. The company employs advanced proprietary technologies, including DuoBody, HexaBody, DuoHexaBody, and HexElect, to create innovative therapies designed to meet unmet medical needs. Genmab's leading product, Darzalex, developed in partnership with Johnson & Johnson, is recognized as the standard treatment for multiple myeloma. In addition to Darzalex, the company's portfolio includes Tepezza for thyroid eye disease, Kesimpta for relapsing multiple sclerosis, Rybrevant for non-small cell lung cancer, Tivdak for cervical cancer, and Epkinly, all of which are developed in collaboration with various pharmaceutical partners. Through its commitment to research and development, Genmab aims to deliver transformative therapies that improve patient outcomes.

Chroma Therapeutics

Series D in 2009
Chroma Therapeutics Ltd. is a biotechnology company based in Abingdon, United Kingdom, specializing in the discovery and development of novel small molecule drugs targeting cancer and inflammatory disorders. Founded in 2000, Chroma leverages chromatin biology and innovative cell accumulation techniques to create its product pipeline. Key products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor designed for cancer treatment; and CHR-2845, focused on hematological malignancies. The company is recognized for its systematic assembly of intellectual property in chromatin biology and has established a strong network of academic collaborations to enhance its research and development efforts.

Stiefel

Acquisition in 2009
Stiefel Laboratories, a subsidiary of GlaxoSmithKline, is a leading global company focused exclusively on dermatology and skin science. It operates more than 30 wholly-owned subsidiaries and six manufacturing plants across various countries, supported by a global research and development network. With a workforce of nearly 3,500 associates, Stiefel is dedicated to delivering innovative ethical, over-the-counter, and aesthetic dermatological products to customers in over 100 countries. Notable brands under its portfolio include Sarna, Duac Topical Gel, Olux, and Brevoxyl. The company invests over $100 million annually in developing advanced skin health solutions, reflecting its commitment to improving current treatments and exploring future innovations in dermatology.

Genelabs Technologies

Acquisition in 2008
Genelabs Technologies Inc., founded in 1983 and headquartered in Redwood City, California, is a biopharmaceutical company focused on the discovery and development of therapies for infectious diseases. The company has a product pipeline that includes projects targeting hepatitis C virus infection, as well as late-stage clinical assets such as an investigational vaccine for hepatitis E virus, which is being developed in collaboration with GlaxoSmithKline. Another notable asset is Prestara, an investigational drug for systemic lupus erythematosus. Genelabs Technologies has established collaborative agreements with the Novartis Institutes for BioMedical Research to advance research on hepatitis C virus polymerase and with the National Health Research Institutes and Genovate Biotechnology Co., Ltd. to develop compounds targeting the hepatitis C virus. In 2009, Genelabs Technologies was acquired by SmithKline Beecham Corporation.

BMS - Egyptian Mature Products Business

Acquisition in 2008
BMS - Egyptian Mature Products Business provides pharmaceutical products.

Sirtris Pharmaceuticals

Acquisition in 2008
[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Reliant Pharmaceuticals

Acquisition in 2007
Reliant Pharmaceuticals specializes in the development and marketing of cardiovascular pharmaceutical products. Established in 1999 and headquartered in Liberty Corner, New Jersey, the company offers a range of medications aimed at treating conditions such as hypertension, elevated cholesterol, and acid reflux disease. Its product lineup includes Axid for acid reflux, InnoPran XL and DynaCirc CR for hypertension, Omacor for high triglycerides, and Rythmol SR for coronary heart disease management. Reliant Pharmaceuticals focuses on acquiring and developing branded therapies, targeting mid- to late-stage clinical development for innovative drug delivery technologies and formulations. The company's products are distributed to physicians across primary care and specialized medical fields.

Praecis Pharmaceuticals

Acquisition in 2006
Praecis Pharmaceuticals, Inc. operates as a biopharmaceutical company, engages in the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.

Domantis

Acquisition in 2006
Domantis Ltd. develops antibody molecules. Domantis Ltd. offers dual targeting human domain antibodies, which are used against cytokine targets for inflammatory diseases, tumour antigens present on the same tumour cells, and tumour growth/angiogenic factors for solid tumours; human domain antibodies with tailored serum half-life that are customized to achieve the desired therapeutic effect; human domain antibodies for diverse therapeutic targets, which are suited to inhibit receptor targets; and injectable and non-injectable human domain antibodies that treat diseases of the lung, as well as disorders of the gastro-intestinal tract.

CNS

Acquisition in 2006
CNS, Inc. was acquired by GlaxoSmithKline Consumer Healthcare, L.P. CNS, Inc. engages in the development and marketing of consumer health care products for better breathing and digestive health markets. The company’s primary products include Breathe Right nasal strips, a nonprescription single-use disposable device that improves breathing by opening the nasal passages; Breathe Right Snore Relief throat spray, a drug-free product that addresses the snoring condition; Breathe Right Vapor Shot! personal vaporizer; Breathe Right saline nasal spray; and FiberChoice, an orange-flavored chewable fiber tablet that supplements the consumer’s daily intake of dietary fiber. CNS markets its products through direct sales force and national brokerage organizations to mass merchandise stores, drug stores, grocery stores, warehouse clubs, military base stores, and online retailers in the United States, as well as through distributors, sales representatives, and suppliers internationally. The company was founded in 1982 and is headquartered in Minneapolis, Minnesota. Source : (Businessweek) {http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=171706}

ID Biomedical

Acquisition in 2005
ID Biomedical Corporation develops and markets vaccine products. The company markets Fluviral, an injectable vaccine for influenza, as well as NeisVac-C for Meningococcal Group C disease in Canada. It also distributes NeisVac-C under license from Baxter Corporation.

Corixa

Acquisition in 2005
Corixa was a developer of immunotherapeutics founded in 1994, dedicated to treating and preventing autoimmune diseases, cancer, and infectious diseases by understanding and directing the immune system. The company engaged in various preclinical development programs, including BEXXAR® therapy and MELACINE® vaccine. Corixa focused on immunotherapeutic products, possessing a broad technology platform that facilitated integrated vaccine design and the use of proprietary product components independently. The company established partnerships with numerous pharmaceutical developers and marketers to enhance the availability of its products. In July 2005, Corixa was acquired by GlaxoSmithKline, which utilized Corixa's MPL adjuvant in some of its vaccines. However, Corixa ultimately ceased operations in March 2006.

Europharm Holding SA

Acquisition in 2003
Europharm Holding SA distributes pharmaceutical products. Europharm Holding operates as a subsidiary of GlaxoSmithKline.

Block Drug Co.

Acquisition in 2001
Block Drug Co., Inc. manufactures denture care products, oral health care products, consumer over-the-counter medications, and professional dental products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.